Sunday, 20 September 2026European Markets

NORDIC NANOVECTOR Stock Impressive Fall 15% So Far On Monday, Underperforms Market

Loading stream...

(VIANEWS) - Shares of NORDIC NANOVECTOR (Oslo Børs Benchmark Index_GI: NANOV.OL) fell by a staggering 15.88% to kr1.88 at 14:37 EST on Monday, following the last session's downward trend. Oslo Børs Benchmark Index_GI is falling 0.32% to kr1,227.59, after three successive sessions in a row of gains. This seems, up until now, a somewhat bearish trend exchanging session today.

NORDIC NANOVECTOR's last close was kr2.24, 71.27% under its 52-week high of kr7.78.

About NORDIC NANOVECTOR

Nordic Nanovector ASA, a biopharmaceutical company, develops therapeutics for hematological cancers in Norway. The company's lead product candidate is Betalutin, a CD37-targeting radioimmunotherapy for the treatment of patients with non-hodgkin lymphoma. Its preclinical development products include Humalutin for treatment of non-Hodgkin's lymphoma; Alpha37, a CD37-targeting radioimmunotherapy for treating chronic lymphatic leukemia; and Multiple fully humanized anti-CD37 antibodies for treatment of haematological cancers and autoimmune diseases. The company is also developing 89Zr-NNV003, a CD37-targeting companion PET diagnostic for detection and dosimetry of CD37 expressing tumors. The company has collaboration agreements with Orano Med; Paul Scherrer Institute; ArevaMed; LegoChem Bio; and Heidelberg Pharma. It also has a research collaboration with the University of Pennsylvania development of a CD37-targeting CAR-T in haematological cancers. The company was formerly known as Nordic Nanovector AS and changed its name to Nordic Nanovector ASA in 2014. Nordic Nanovector ASA was incorporated in 2009 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, NORDIC NANOVECTOR has a trailing twelve months EPS of kr-7.91.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -304.6%.

Moving Average

NORDIC NANOVECTOR's worth is way above its 50-day moving average of kr0.86 and way above its 200-day moving average of kr1.07.

Volume

Today's last reported volume for NORDIC NANOVECTOR is 7184709 which is 451.66% above its average volume of 1302360.

Volatility

NORDIC NANOVECTOR's last week, last month's, and last quarter's current intraday variation average was 34.34%, 8.64%, and 6.34%.

NORDIC NANOVECTOR's highest amplitude of average volatility was 47.20% (last week), 13.40% (last month), and 6.34% (last quarter).

Yearly Top and Bottom Value

NORDIC NANOVECTOR's stock is valued at kr1.88 at 14:37 EST, way under its 52-week high of kr7.78 and way higher than its 52-week low of kr0.65.

More news about NORDIC NANOVECTOR (NANOV.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Boom Hits a Fork: Slowdown Calls Clash with Capex Confidence as Markets Get Nervous
Dario Amodei's repeated calls for a global slowdown in frontier AI development, echoed by Microsoft's new humanist AI code of conduct and FTC antitrust caution, are being publicly rejected by Nvidia and Meta leadership even as hyperscaler spending draws fresh skeptical scrutiny (Wachter's analysis, Burry-style overbuilding worries) and weak guidance from Adobe and a post-slowdown-comment selloff in GE Vernova signal investor jitters. Meanwhile wealth and security effects of the AI race keep compounding — Zhang Yiming's fortune surging on AI-driven ByteDance value, a Chinese hacking firm weaponizing AI against stolen government secrets, and low-quality AI-generated products (an AI sitcom, a spam-flooding agent platform) fueling backlash even as adoption races ahead.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,982
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,982 facts checked against source5,299 source documents archived
Query this data → isubstrate.com